RxDoctor Payments Data

Sean Smith, MD

Physical Medicine & Rehabilitation · Saint Louis, MONPI 1700268968

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,111 of the $1,581 with a category attached, or 70.2%. Pacira Pharmaceuticals Incorporated accounts for 85.3% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2024 at $1,349 and has fallen 90.1% since, to $134 in 2025.

$1,581in general payments, 2019–2025

Across 12 payments — averaging $131.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pacira Pharmaceuticals Incorporated$1K
  • Biogen$134
  • AbbVie$98
$169,524in research payments, 2019–2025

Across 11 payments — averaging $15,411 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Ionis Pharmaceuticals, Inc.$139K
  • Pacira Pharmaceuticals Incorporated$30K

What the payments were for

  • Travel & lodging$1,11170%
  • Food & beverage$47130%

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pacira Pharmaceuticals Incorporated9$1,349
Biogen2$134
AbbVie1$98

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,581 in reported general payments places this provider in the 80th percentile of 182 physical medicine & rehabilitation providers in Missouri.

See all physical medicine & rehabilitation providers in Missouri

Medicare billing

Part B allowed, 2024
$41,518
Medicare patients
107
Services billed
369

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone69$993,350
HizentraImmun Glob G(Igg)/Pro/Iga 0-5027$464,373
SkyclarysOmaveloxolone11$352,237
RelyvrioSod Phenylbutyrat/Taurursodiol22$281,586
Riluzole108$17,644
NuedextaDextromethorphan Hbr/Quinidine11$17,012
Mycophenolate Mofetil34$3,015
Atropine Sulfate16$981
Duloxetine Hcl40$683
Baclofen71$668
Gabapentin27$617
Pyridostigmine Bromide11$558
Ipratropium Bromide15$359
Prednisone48$186
Amitriptyline Hcl29$167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenSkyclarys$134$352,23711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 182 physical medicine & rehabilitation providers in Missouri.

Other physical medicine & rehabilitation in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →